Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin‐releasing peptide levels
BACKGROUND Progastrin‐releasing peptide (proGRP) is a specific tumor marker in patients with small cell lung carcinoma (SCLC). It has been reported that serum proGRP levels rarely are elevated in patients with nonsmall cell lung carcinoma (NSCLC); the reported frequency is
Gespeichert in:
| Veröffentlicht in: | Cancer 1998-03, Vol.82 (6), p.1056-1061 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1061 |
|---|---|
| container_issue | 6 |
| container_start_page | 1056 |
| container_title | Cancer |
| container_volume | 82 |
| creator | Goto, Koichi Kodama, Tetsuro Hojo, Fumihiko Kubota, Kaoru Kakinuma, Ryutaro Matsumoto, Taketoshi Ohmatsu, Hironobu Sekine, Ikuo Nagai, Kanji Nishiwaki, Yutaka |
| description | BACKGROUND
Progastrin‐releasing peptide (proGRP) is a specific tumor marker in patients with small cell lung carcinoma (SCLC). It has been reported that serum proGRP levels rarely are elevated in patients with nonsmall cell lung carcinoma (NSCLC); the reported frequency is |
| doi_str_mv | 10.1002/(SICI)1097-0142(19980315)82:6<1056::AID-CNCR7>3.0.CO;2-C |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79730671</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79730671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4787-a4e94c75e8d5c718926850bc6899fb90f4d4e6b2deb26c67a8347beaa0dd16333</originalsourceid><addsrcrecordid>eNqFkcuKFDEUhgtRxnH0EYRaiMwsqs2lKpceEYfy1jDY4AXG1SGVOtUdqUubVDvMzq07n9EnMWW3vVFwk5Dzf-fw5_xJ8pySGSWEPTl9vygXZ5RomRGas1OqtSKcFmeKzcVTSgoxn18sXmTl2_KdfMZnZFYuz1lW3kqOD023k2NCiMqKnF_dTe6F8Dk-JSv4UXKkCyJ4ro-T72XremeHjRnXQzusnE3t2nhjR_QujM6GdGjSqDrsx5Beu3Gd9kMfOtO2qcV4tNt-lVrjreuHzuwIbPGrGbFOA_ptl278sDJh9K7_-e2Hj6IJLjZtcDO6GtMIYxvuJ3ca0wZ8sL9Pko-vXn4o32SXy9eL8uIys7lUMjM56tzKAlVdWEmVZkIVpLJCad1UmjR5naOoWI0VE1ZIo3guKzSG1DUVnPOT5PFubnT1ZYthhM6F6Semx2EbQGrJiZA0glc70PohBI8NbLzrjL8BSmBKCWBKCaaFw7Rw-JMSKAYCppQAYkrwOyXgQKBcAoMyjn6497CtOqwPg_exRP3RXjfBmrbxprcuHDBGVSEKFrFPO-zatXjzl73_u_uXuV2B_wJllb_u</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79730671</pqid></control><display><type>article</type><title>Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin‐releasing peptide levels</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Goto, Koichi ; Kodama, Tetsuro ; Hojo, Fumihiko ; Kubota, Kaoru ; Kakinuma, Ryutaro ; Matsumoto, Taketoshi ; Ohmatsu, Hironobu ; Sekine, Ikuo ; Nagai, Kanji ; Nishiwaki, Yutaka</creator><creatorcontrib>Goto, Koichi ; Kodama, Tetsuro ; Hojo, Fumihiko ; Kubota, Kaoru ; Kakinuma, Ryutaro ; Matsumoto, Taketoshi ; Ohmatsu, Hironobu ; Sekine, Ikuo ; Nagai, Kanji ; Nishiwaki, Yutaka</creatorcontrib><description>BACKGROUND
Progastrin‐releasing peptide (proGRP) is a specific tumor marker in patients with small cell lung carcinoma (SCLC). It has been reported that serum proGRP levels rarely are elevated in patients with nonsmall cell lung carcinoma (NSCLC); the reported frequency is <3%. The purpose of this study was to examine the clinicopathologic features of NSCLC patients with high serum proGRP levels.
METHODS
The authors measured serum proGRP levels with a TND‐4 kit, a newly developed enzyme‐linked immunoadsorbent assay, in 544 NSCLC and 206 SCLC patients. Pathologic features were examined using conventional hematoxylin and eosin staining and histochemical and immunohistochemical staining using polyclonal antibodies to proGRP, chromogranin A, calcitonin, and monoclonal antibody to the neural cell adhesion molecule (NCC‐Lu‐243).
RESULTS
The serum proGRP levels were elevated in 140 SCLC patients (68.0%) and in 23 NSCLC patients (4.2%). Seven of these 23 NSCLC patients had serum proGRP levels ≥ 100 pg/mL. They included two patients with renal dysfunction, one patient diagnosed cytologically with adenocarcinoma without undergoing precise pathologic examination, two patients diagnosed histologically with squamous cell carcinoma with foci of small cell elements, and two patients diagnosed with large cell neuroendocrine carcinoma and poorly differentiated adenocarcinoma, respectively, which showed neuroendocrine differentiation on immunohistologic analysis. The remaining 16 NSCLC patients had serum proGRP levels < 70 pg/mL.
CONCLUSIONS
Nearly all NSCLC patients had serum proGRP levels < 100 pg/mL. However, if an NSCLC patient presents with a proGRP level ≥ 100 pg/mL, the clinicopathologic features must be examined with regard to the small cell component, neuroendocrine differentiation, and renal dysfunction. Cancer 1998; 82:1056‐61. © 1998 American Cancer Society.
In the current study, nearly all nonsmall cell lung carcinoma (NSCLC) patients had serum progastrin‐releasing peptide levels < 100 pg/mL. However, if an NSCLC patient presents with a level ≥ 100 pg/mL, the clinicopathologic features must be examined with regard to the small cell component, neuroendocrine differentiation, and renal dysfunction.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/(SICI)1097-0142(19980315)82:6<1056::AID-CNCR7>3.0.CO;2-C</identifier><identifier>PMID: 9506349</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Adenocarcinoma - diagnosis ; Adenocarcinoma - pathology ; Adult ; Aged ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Carcinoma, Large Cell - diagnosis ; Carcinoma, Large Cell - pathology ; Carcinoma, Non-Small-Cell Lung - diagnosis ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Squamous Cell - diagnosis ; Carcinoma, Squamous Cell - pathology ; Enzyme-Linked Immunosorbent Assay ; Female ; Gastrins - blood ; Humans ; Lung ; Lung Neoplasms - diagnosis ; Lung Neoplasms - pathology ; Male ; Medical sciences ; Middle Aged ; neuroendocrine carcinoma ; nonsmall cell lung carcinoma ; Pneumology ; progastrin‐releasing peptide (proGRP) ; Protein Precursors - blood ; renal dysfunction ; Renal Insufficiency - physiopathology ; small cell lung carcinoma ; Tumors of the respiratory system and mediastinum</subject><ispartof>Cancer, 1998-03, Vol.82 (6), p.1056-1061</ispartof><rights>Copyright © 1998 American Cancer Society</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4787-a4e94c75e8d5c718926850bc6899fb90f4d4e6b2deb26c67a8347beaa0dd16333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291097-0142%2819980315%2982%3A6%3C1056%3A%3AAID-CNCR7%3E3.0.CO%3B2-C$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291097-0142%2819980315%2982%3A6%3C1056%3A%3AAID-CNCR7%3E3.0.CO%3B2-C$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1413,1429,27906,27907,45556,45557,46391,46815</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2185652$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9506349$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goto, Koichi</creatorcontrib><creatorcontrib>Kodama, Tetsuro</creatorcontrib><creatorcontrib>Hojo, Fumihiko</creatorcontrib><creatorcontrib>Kubota, Kaoru</creatorcontrib><creatorcontrib>Kakinuma, Ryutaro</creatorcontrib><creatorcontrib>Matsumoto, Taketoshi</creatorcontrib><creatorcontrib>Ohmatsu, Hironobu</creatorcontrib><creatorcontrib>Sekine, Ikuo</creatorcontrib><creatorcontrib>Nagai, Kanji</creatorcontrib><creatorcontrib>Nishiwaki, Yutaka</creatorcontrib><title>Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin‐releasing peptide levels</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND
Progastrin‐releasing peptide (proGRP) is a specific tumor marker in patients with small cell lung carcinoma (SCLC). It has been reported that serum proGRP levels rarely are elevated in patients with nonsmall cell lung carcinoma (NSCLC); the reported frequency is <3%. The purpose of this study was to examine the clinicopathologic features of NSCLC patients with high serum proGRP levels.
METHODS
The authors measured serum proGRP levels with a TND‐4 kit, a newly developed enzyme‐linked immunoadsorbent assay, in 544 NSCLC and 206 SCLC patients. Pathologic features were examined using conventional hematoxylin and eosin staining and histochemical and immunohistochemical staining using polyclonal antibodies to proGRP, chromogranin A, calcitonin, and monoclonal antibody to the neural cell adhesion molecule (NCC‐Lu‐243).
RESULTS
The serum proGRP levels were elevated in 140 SCLC patients (68.0%) and in 23 NSCLC patients (4.2%). Seven of these 23 NSCLC patients had serum proGRP levels ≥ 100 pg/mL. They included two patients with renal dysfunction, one patient diagnosed cytologically with adenocarcinoma without undergoing precise pathologic examination, two patients diagnosed histologically with squamous cell carcinoma with foci of small cell elements, and two patients diagnosed with large cell neuroendocrine carcinoma and poorly differentiated adenocarcinoma, respectively, which showed neuroendocrine differentiation on immunohistologic analysis. The remaining 16 NSCLC patients had serum proGRP levels < 70 pg/mL.
CONCLUSIONS
Nearly all NSCLC patients had serum proGRP levels < 100 pg/mL. However, if an NSCLC patient presents with a proGRP level ≥ 100 pg/mL, the clinicopathologic features must be examined with regard to the small cell component, neuroendocrine differentiation, and renal dysfunction. Cancer 1998; 82:1056‐61. © 1998 American Cancer Society.
In the current study, nearly all nonsmall cell lung carcinoma (NSCLC) patients had serum progastrin‐releasing peptide levels < 100 pg/mL. However, if an NSCLC patient presents with a level ≥ 100 pg/mL, the clinicopathologic features must be examined with regard to the small cell component, neuroendocrine differentiation, and renal dysfunction.</description><subject>Adenocarcinoma - diagnosis</subject><subject>Adenocarcinoma - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Large Cell - diagnosis</subject><subject>Carcinoma, Large Cell - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnosis</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Squamous Cell - diagnosis</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Gastrins - blood</subject><subject>Humans</subject><subject>Lung</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>neuroendocrine carcinoma</subject><subject>nonsmall cell lung carcinoma</subject><subject>Pneumology</subject><subject>progastrin‐releasing peptide (proGRP)</subject><subject>Protein Precursors - blood</subject><subject>renal dysfunction</subject><subject>Renal Insufficiency - physiopathology</subject><subject>small cell lung carcinoma</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcuKFDEUhgtRxnH0EYRaiMwsqs2lKpceEYfy1jDY4AXG1SGVOtUdqUubVDvMzq07n9EnMWW3vVFwk5Dzf-fw5_xJ8pySGSWEPTl9vygXZ5RomRGas1OqtSKcFmeKzcVTSgoxn18sXmTl2_KdfMZnZFYuz1lW3kqOD023k2NCiMqKnF_dTe6F8Dk-JSv4UXKkCyJ4ro-T72XremeHjRnXQzusnE3t2nhjR_QujM6GdGjSqDrsx5Beu3Gd9kMfOtO2qcV4tNt-lVrjreuHzuwIbPGrGbFOA_ptl278sDJh9K7_-e2Hj6IJLjZtcDO6GtMIYxvuJ3ca0wZ8sL9Pko-vXn4o32SXy9eL8uIys7lUMjM56tzKAlVdWEmVZkIVpLJCad1UmjR5naOoWI0VE1ZIo3guKzSG1DUVnPOT5PFubnT1ZYthhM6F6Semx2EbQGrJiZA0glc70PohBI8NbLzrjL8BSmBKCWBKCaaFw7Rw-JMSKAYCppQAYkrwOyXgQKBcAoMyjn6497CtOqwPg_exRP3RXjfBmrbxprcuHDBGVSEKFrFPO-zatXjzl73_u_uXuV2B_wJllb_u</recordid><startdate>19980315</startdate><enddate>19980315</enddate><creator>Goto, Koichi</creator><creator>Kodama, Tetsuro</creator><creator>Hojo, Fumihiko</creator><creator>Kubota, Kaoru</creator><creator>Kakinuma, Ryutaro</creator><creator>Matsumoto, Taketoshi</creator><creator>Ohmatsu, Hironobu</creator><creator>Sekine, Ikuo</creator><creator>Nagai, Kanji</creator><creator>Nishiwaki, Yutaka</creator><general>John Wiley & Sons, Inc</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980315</creationdate><title>Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin‐releasing peptide levels</title><author>Goto, Koichi ; Kodama, Tetsuro ; Hojo, Fumihiko ; Kubota, Kaoru ; Kakinuma, Ryutaro ; Matsumoto, Taketoshi ; Ohmatsu, Hironobu ; Sekine, Ikuo ; Nagai, Kanji ; Nishiwaki, Yutaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4787-a4e94c75e8d5c718926850bc6899fb90f4d4e6b2deb26c67a8347beaa0dd16333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adenocarcinoma - diagnosis</topic><topic>Adenocarcinoma - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Large Cell - diagnosis</topic><topic>Carcinoma, Large Cell - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnosis</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Squamous Cell - diagnosis</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Gastrins - blood</topic><topic>Humans</topic><topic>Lung</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>neuroendocrine carcinoma</topic><topic>nonsmall cell lung carcinoma</topic><topic>Pneumology</topic><topic>progastrin‐releasing peptide (proGRP)</topic><topic>Protein Precursors - blood</topic><topic>renal dysfunction</topic><topic>Renal Insufficiency - physiopathology</topic><topic>small cell lung carcinoma</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goto, Koichi</creatorcontrib><creatorcontrib>Kodama, Tetsuro</creatorcontrib><creatorcontrib>Hojo, Fumihiko</creatorcontrib><creatorcontrib>Kubota, Kaoru</creatorcontrib><creatorcontrib>Kakinuma, Ryutaro</creatorcontrib><creatorcontrib>Matsumoto, Taketoshi</creatorcontrib><creatorcontrib>Ohmatsu, Hironobu</creatorcontrib><creatorcontrib>Sekine, Ikuo</creatorcontrib><creatorcontrib>Nagai, Kanji</creatorcontrib><creatorcontrib>Nishiwaki, Yutaka</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goto, Koichi</au><au>Kodama, Tetsuro</au><au>Hojo, Fumihiko</au><au>Kubota, Kaoru</au><au>Kakinuma, Ryutaro</au><au>Matsumoto, Taketoshi</au><au>Ohmatsu, Hironobu</au><au>Sekine, Ikuo</au><au>Nagai, Kanji</au><au>Nishiwaki, Yutaka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin‐releasing peptide levels</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1998-03-15</date><risdate>1998</risdate><volume>82</volume><issue>6</issue><spage>1056</spage><epage>1061</epage><pages>1056-1061</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND
Progastrin‐releasing peptide (proGRP) is a specific tumor marker in patients with small cell lung carcinoma (SCLC). It has been reported that serum proGRP levels rarely are elevated in patients with nonsmall cell lung carcinoma (NSCLC); the reported frequency is <3%. The purpose of this study was to examine the clinicopathologic features of NSCLC patients with high serum proGRP levels.
METHODS
The authors measured serum proGRP levels with a TND‐4 kit, a newly developed enzyme‐linked immunoadsorbent assay, in 544 NSCLC and 206 SCLC patients. Pathologic features were examined using conventional hematoxylin and eosin staining and histochemical and immunohistochemical staining using polyclonal antibodies to proGRP, chromogranin A, calcitonin, and monoclonal antibody to the neural cell adhesion molecule (NCC‐Lu‐243).
RESULTS
The serum proGRP levels were elevated in 140 SCLC patients (68.0%) and in 23 NSCLC patients (4.2%). Seven of these 23 NSCLC patients had serum proGRP levels ≥ 100 pg/mL. They included two patients with renal dysfunction, one patient diagnosed cytologically with adenocarcinoma without undergoing precise pathologic examination, two patients diagnosed histologically with squamous cell carcinoma with foci of small cell elements, and two patients diagnosed with large cell neuroendocrine carcinoma and poorly differentiated adenocarcinoma, respectively, which showed neuroendocrine differentiation on immunohistologic analysis. The remaining 16 NSCLC patients had serum proGRP levels < 70 pg/mL.
CONCLUSIONS
Nearly all NSCLC patients had serum proGRP levels < 100 pg/mL. However, if an NSCLC patient presents with a proGRP level ≥ 100 pg/mL, the clinicopathologic features must be examined with regard to the small cell component, neuroendocrine differentiation, and renal dysfunction. Cancer 1998; 82:1056‐61. © 1998 American Cancer Society.
In the current study, nearly all nonsmall cell lung carcinoma (NSCLC) patients had serum progastrin‐releasing peptide levels < 100 pg/mL. However, if an NSCLC patient presents with a level ≥ 100 pg/mL, the clinicopathologic features must be examined with regard to the small cell component, neuroendocrine differentiation, and renal dysfunction.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>9506349</pmid><doi>10.1002/(SICI)1097-0142(19980315)82:6<1056::AID-CNCR7>3.0.CO;2-C</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 1998-03, Vol.82 (6), p.1056-1061 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79730671 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adenocarcinoma - diagnosis Adenocarcinoma - pathology Adult Aged Biological and medical sciences Biomarkers, Tumor - blood Carcinoma, Large Cell - diagnosis Carcinoma, Large Cell - pathology Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Squamous Cell - diagnosis Carcinoma, Squamous Cell - pathology Enzyme-Linked Immunosorbent Assay Female Gastrins - blood Humans Lung Lung Neoplasms - diagnosis Lung Neoplasms - pathology Male Medical sciences Middle Aged neuroendocrine carcinoma nonsmall cell lung carcinoma Pneumology progastrin‐releasing peptide (proGRP) Protein Precursors - blood renal dysfunction Renal Insufficiency - physiopathology small cell lung carcinoma Tumors of the respiratory system and mediastinum |
| title | Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin‐releasing peptide levels |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T10%3A00%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinicopathologic%20characteristics%20of%20patients%20with%20nonsmall%20cell%20lung%20carcinoma%20with%20elevated%20serum%20progastrin%E2%80%90releasing%20peptide%20levels&rft.jtitle=Cancer&rft.au=Goto,%20Koichi&rft.date=1998-03-15&rft.volume=82&rft.issue=6&rft.spage=1056&rft.epage=1061&rft.pages=1056-1061&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/(SICI)1097-0142(19980315)82:6%3C1056::AID-CNCR7%3E3.0.CO;2-C&rft_dat=%3Cproquest_cross%3E79730671%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79730671&rft_id=info:pmid/9506349&rfr_iscdi=true |